Table 3 Individual control subject characteristics
From: Insights in to the pathogenesis of axial spondyloarthropathy based on gene expression profiles
Subject | Data-set | Gender | Race | Medications |
|---|---|---|---|---|
19 | 1 | F | Caucasian | Alphagan OP, Xalatan OP |
20 | 1 | F | Caucasian | _ |
21 | 1 | F | Caucasian | Atorvastatin, losartan, atenolol, aspirin, hydrochlorothiazide |
22 | 1 | M | Caucasian | Atorvastatin, glargine, lisinopril, fluoxetine, amlodipine, Systane OP |
23 | 1 | F | Caucasian | Levothyroxine, sertraline |
24 | 1 | M | Caucasian | Diazepam, simvastatin, aspirin |
25 | 1 | M | Caucasian | Ibuprofen |
26 | 1 | F | Caucasian | _ |
27 | 1 | F | Caucasian | Sertraline, desogestrel/ethinyl estradiol |
28 | 1 | M | Caucasian | Ibuprofen, diazepam, acetaminophen/aspirin, esomeprazole, sumatriptan |
29 | 1 | F | Caucasian | _ |
30 | 1 | F | Asian | Trazodone, sertraline, levonorgestrel/ethinyl, estradiol, atorvastatin, ibuprofen, acetaminophen |
31 | 2 | F | Caucasian | Acetaminophen, ibuprofen |
32 | 2 | F | Caucasian | _ |
33 | 2 | F | Mixed* | _ |
34 | 2 | F | Caucasian | Ibuprofen |
35 | 2 | F | Caucasian | Etonogestrel/ethinyl estradiol VA |
36 | 2 | F | Caucasian | _ |
37 | 2 | F | Caucasian | Etonogestrel/ethinyl estradiol VA, cetirizine |
38 | 2 | F | Caucasian | Desogestrel/ethinyl estradiol |
39 | 2 | F | Caucasian | _ |
40 | 2 | F | Caucasian | Estradiol 0.01% cream, levonorgestrel |
41 | 2 | M | Caucasian | _ |
42 | 2 | F | Caucasian | Duloxetine, valacyclovir, cyclobenzaprine |
43 | 2 | F | Caucasian | _ |